Title
Short-term morbidity in transdiaphragmatic cardiophrenic lymph node resection for advanced stage gynecologic cancer.

Permalink
https://escholarship.org/uc/item/86v1h2sv

Authors
LaFargue, CJ
Sawyer, BT
Bristow, RE

Publication Date
2016-08-01

DOI
10.1016/j.gore.2016.05.006

Peer reviewed
Case series

Short-term morbidity in transdiaphragmatic cardiophrenic lymph node resection for advanced stage gynecologic cancer

C.J. LaFargue a,⁎, B.T. Sawyer a, R.E. Bristow a,b

a Department of Obstetrics and Gynecology, University of California, Irvine - Medical Center, Orange, CA, United States
b Division of Gynecologic Oncology, University of California, Irvine - Medical Center, Orange, CA, United States

ARTICLE INFO

Article history:
Received 13 March 2016
Received in revised form 25 April 2016
Accepted 22 May 2016
Available online 24 May 2016

Keywords:
Ovarian cancer
Cytoreductive surgery
Diaphragm resection
Cardiophrenic lymph nodes
Post-operative morbidity

ABSTRACT

Ovarian cancer is commonly diagnosed at an advanced stage, with disease involving the upper abdomen. The finding of enlarged cardiophrenic lymph nodes (CPLNs) on pre-operative imaging often indicates the presence of malignant spread to the mediastinum. Surgical resection of CPLN through a transdiaphragmatic approach can help to achieve cytoreduction to no gross residual. A retrospective chart review was conducted on all patients who underwent transdiaphragmatic cardiophrenic lymph node resection from 8/1/11 through 2/1/15. All relevant pre-, intra-, and post-operative characteristics and findings were recorded. A brief description of the surgical technique is included for reference. Eleven patients were identified who had undergone transdiaphragmatic resection of cardiophrenic lymph nodes. Malignancy was identified in 18/21 (86%) of total lymph nodes submitted. The median number of post-operative days was 7. The overall post-operative morbidity associated with CPLN resection was low, with the most common finding being a small pleural effusion present on chest x-ray between POD# 3–5 (55%). Transdiaphragmatic CPLN resection is a feasible procedure with relatively minor short-term post-operative morbidities that can be used to achieve cytoreduction to no gross residual disease.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cancer of the ovary is a particularly insidious disease that is commonly diagnosed at an advanced stage. In 2015, the American Cancer Society estimated that 21,290 new cases were diagnosed and 14,180 women died of this disease (American Cancer Society, Inc. Cancer Facts, and Figures, 2015). One of the main reasons for such a high associated mortality is that approximately 65% of patients are initially diagnosed at International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV (Pecorelli et al., 1998). Primary cytoreductive surgery to no gross residual (NGR) disease has consistently been found to be one of the most important prognostic indicators in patients with advanced stage ovarian cancer and remains the only factor under the control of the operating surgeon. Furthermore, statistically significant differences in recurrence and survival have been observed when residual tumor volume was reported as either microscopic (NGR), 0.1 to 5.0 cm, or >5.0 cm (Winter et al., 2008).

Various surgical techniques have previously been described to achieve complete resection of diaphragmatic and CPLN related disease. Bashir et al. described a procedure for full thickness diaphragm resection which in addition to removing bulky diaphragm disease, allowed for access to the pleural and pericardial space (Bashir et al., 2010). In addition, our group recently published a surgical video displaying the technique of diaphragm resection and transdiaphragmatic resection of CPLNs (LaFargue and Bristow, 2015). Video-assisted thoracic surgery (VATS) has also been shown to be a successful modality for achieving resection of CPLNs (Lim et al., 2009).

The current case series was compiled to further define the pre-, intra-, and post-operative characteristics of patients undergoing transdiaphragmatic resection of CPLNs in advanced gynecologic cancer and delineate the associated short-term morbidities and time to adjuvant chemotherapy.

2. Methods

The study design was a retrospective review performed in the division of Gynecologic Oncology at the University of California Irvine Medical Center. All patients who underwent a transdiaphragmatic cardiophrenic lymph node resection from 8/1/11 through 2/1/15 as part of a primary or secondary cytoreductive surgery were selected for detailed review. Each identified subject had transdiaphragmatic CPLN resection performed in an effort to achieve cytoreduction to no gross residual disease. There were only two different physicians who were listed as the primary surgeon for all patients included in this report. All of the CPLN resection procedures were performed by the same gynecologic oncologist with the assistance of either the primary surgeon or a
2.1. Surgical technique

In most cases, enlarged cardiophrenic lymph nodes were first identified on pre-operative CT imaging (Fig. 1). For the patients in which pre-operative imaging did not show lymphadenopathy, the decision was made to proceed with CPLN resection based on an intraoperative assessment consisting of the degree of diaphragm involvement and palpation of the pericardial space. The surgical technique used to perform full-thickness diaphragm resection and CPLN resection has been previously described and illustrated (Bashir et al., 2010; LaFargue and Bristow, 2015). In brief, full exposure of the diaphragm peritoneum is achieved after mobilization of the liver. The diaphragm is then incised using electrocautery, the pleural space is explored, and the cardiophrenic nodes are resected using a vessel sealing-cutting device (Fig. 2). A 15F, round Jackson Pratt (JP) drain is then used as an alternative to the standard chest tube and placed through the diaphragmatic defect into the pleural cavity under direct vision and brought out through a separate stab incision in the mid-axillary line above the seventh or eighth rib. The diaphragmatic defect is then closed using a non-absorbable suture (2-0 polypropylene in figure-of-eight stitches). The Jackson-Pratt drain is then connected to suction to evacuate the pneumothorax. If no chest tube is placed, prior to tying the last stitch, a fenestrated 16F Robinson catheter attached to wall suction is placed into the pleural cavity to remove the pneumothorax and withdrawn as the last knot is tied. The “bubble test” is then performed to evaluate for any air leak by filling the right upper quadrant with saline solution and delivering several large mechanical inspiratory breaths while inspecting the repair for extravasation of air bubbles. If present, air leaks are oversewn, the pneumothorax evacuated, and the test repeated.

3. Results

3.1. Patient demographics

A total of 11 patients underwent transdiaphragmatic CPLN resection (10 with unilateral CPLN resection, and 1 patient with bilateral resection). Specific patient characteristics are displayed in Table 1. The mean age was 58 years (range 42–71 years), with FIGO stage IVB serous ovarian cancer being the most common stage, histology, and primary tumor site, respectively. One patient included in the study had clear cell uterine cancer. Enlarged cardiophrenic lymph nodes were identified in 7 patients on pre-operative imaging (64%), while the remainder was identified based on intra-operative suspicion.

3.2. Surgical outcomes

Table 2 displays the intra-operative and post-operative findings. The average operative time was 385 min (range 277–568 min), and the average estimated blood loss was 564 cm³ (range 200–900 cm³). Ten patients underwent optimal cytoreduction defined as < 1 cm (91%), while 7 of these patients had no gross residual disease (64%). A prophylactic Jackson-Pratt drain was placed in the pleural cavity, as an alternative chest tube, and brought out through a separate stab incision in the chest in 8 patients (73%).

Intra-operative frozen section of the resected CPLNs was sent in 6 patients, with malignancy being identified in 5 of them. On final pathologic evaluation, the average number and size of CPLNs obtained per patient was 1.9 (range 1–4) and 1.6 cm (range 0.2–2.5 cm), respectively, with final diagnosis of malignancy confirmed in 10 of the 11 total patients. The total number of CPLNs resected from all patients was 21 with malignancy being confirmed in 18 (86%).

The median number of post-operative days was 7 (range 4–37). The overall post-operative morbidity associated with CPLN resection was low with the most common finding being a small pleural effusion.
present on chest x-ray between POD# 3 to 5 (55%). Other morbidities noted on POD# 0–5 were small and moderate pleural effusion as well as small apical pneumothorax. Major complications were rare (occurring in 1 patient only) and consisted of respiratory failure with need for re-intubation and eventual tracheostomy, which was not thought to be related to the CPLN resection. No patients required post-operative thoracostesis for effusion or pneumothorax. The average time to adjuvant chemotherapy was similar in patients who received HIPEC versus those who did not (39 and 38 days, respectively).

4. Discussion

Stage III or IV ovarian cancer by definition involves extrapelvic spread of tumor, however it often presents with tumor involvement of the diaphragm peritoneum and muscle, and has been reported to involve cardiophrenic lymph nodes. In a survey of gynecologic oncologists in 2001, 76.3% of respondents reported that bulky upper abdominal disease precluded complete cytoreductive surgery. In addition, only 24% of respondents reported performing diaphragm resection, and 30% stated they were not experienced with the procedure (Eisenkop and Spirtos, 2001).

The morbidity and mortality associated with such complex and invasive surgical procedures has been previously studied. The most common post-operative complications reported after undergoing diaphragmatic surgery (either peritonectomy or muscle resection) were pleural effusion (5–57%), pneumothorax (0–29%), and pneumonia (0–7%). Serious complications occurred rarely and included pleural effusion requiring thoracostomy or thoracostesis, need for re-operation, and death. Many of these studies however further stratified each complication based on grade/severity and post-operative day of occurrence, noting that the majority of complications occurred on POD# 1–2, were of low severity, and did not delay hospital discharge (Bashir et al., 2010; Chi et al., 2010; Tsolakidis et al., 2010; Sandadi et al., 2014).

Despite such a proactive approach to the surgical cytoreduction of advanced gynecologic cancer, the current small case series demonstrates that transdiaphragmatic CPLN resection is feasible and is accompanied by acceptable postoperative morbidity. When compared to the above reports of patients who underwent aggressive upper abdominal surgery (UAS) for ovarian cancer, the post-operative morbidities we identified did not differ significantly nor did the procedure result in any significant prolongation of postoperative hospital stay. Panici et al. reported that in a study of 120 patients who underwent UAS for ovarian cancer, the median hospital stay for patients with and without complication was 7 vs. 13 days, respectively (Benedetti Panici et al., 2015). In addition, Cliby et al. reported that diaphragm resection as part of cytoreductive surgery for ovarian cancer carries comparable risks to other radical debulking procedures (Cliby et al., 2004). The decision to proceed with extensive cytoreductive procedures must be made carefully and with the intent to achieve cytoreduction to no gross residual disease. Furthermore, multiple studies have demonstrated that patients who had optimal (< 1 cm) or microscopic residual disease had increased survival compared to those with suboptimal resection (Winter et al., 2008; Aletti et al., 2006; Eisenhauer et al., 2006). Given that the size of resected CPLNs in our study ranged from 0.2 to 2.5 cm, removal of mediastinal metastasis may make a significant difference in the ability to achieve optimal cytoreduction to < 1.0 cm.

The short-term morbidity of the patients included in our study was similar to previous reports of patients who underwent diaphragm resection or other aggressive upper abdominal surgery. As the majority of the CPLN specimens were positive for malignancy, the addition of this procedure contributed to achieving cytoreduction to NGR status. This suggests that careful attention should be paid to the lower mediastinum on pre-operative imaging of advanced gynecologic cancer patients — particularly when the diaphragm appears to be involved.

Currently, there is mixed data on the optimal time for initiation of adjuvant chemotherapy after primary cytoreductive surgery. One of the continually recognized prognostic factors for advanced ovarian cancer is residual disease at the conclusion of primary surgery. Aletti et al. reported that time to chemotherapy (TTC) was not a predictor of overall survival, and that concerns regarding the TTC interval should not be used to justify a more conservative approach to primary debulking surgery (Aletti et al., 2007). Although in our small case series TTC data was only available for 7 patients, we found that the addition of CPLN resection did not largely delay initiation of adjuvant chemotherapy, and in fact contributed to achieving R0 status as the majority of the CPLN specimens were positive for malignancy. Furthermore, even in the subset of our patients that had HIPEC performed during surgery, the initiation of adjuvant chemotherapy was only increased by one day. Again however, when considering the small number of patients included in our study, it is difficult to draw any statistical significance from these specific findings.

Some important limitations in our study must be noted before applying the described technique to routine clinical practice. First, we do not yet have recurrence or survival data on the patients included.

---

**Table 1**

| Characteristics                          | N (11 total patients) | %   | Mean | Range |
|-----------------------------------------|-----------------------|-----|------|-------|
| Age                                     |                       |     |      |       |
| Pre-operative CA-125                    |                       |     |      |       |
| <200                                    | 2                     | 18  |      |       |
| >200                                    | 9                     | 82  |      |       |
| Surgery                                 |                       |     |      |       |
| Primary                                | 10                    | 91  |      |       |
| Recurrent                               | 1                     | 9   |      |       |
| Neoadjuvant chemotherapy                | 2                     | 20  |      |       |
| CPLN on pre-op CT                       | 7                     | 64  |      |       |
| Cancer site                             |                       |     |      |       |
| Endometrial                            | 1                     | 9   |      |       |
| Ovary                                  | 8                     | 73  |      |       |
| Peritoneal                              | 1                     | 9   |      |       |
| Fallopian tube                          | 1                     | 9   |      |       |
| Histology                               |                       |     |      |       |
| Serous                                  | 8                     | 73  |      |       |
| Mucinous/serous                        | 1                     | 9   |      |       |
| Endometrioid                           | 1                     | 9   |      |       |
| Clear cell                              | 1                     | 9   |      |       |
| Stage                                   |                       |     |      |       |
| II                                        | 1                     | 10  |      |       |
| III                                      | 9                     | 90  |      |       |
Although the addition of the described procedure did not appear to pose any greater risk than other similarly aggressive surgical procedures, it is unclear as to whether it prolongs progression-free or overall survival. Second, the procedure described was performed by a single gynecologic oncologist at our institution. Although the majority of gynecologic oncologists receive adequate training during fellowship in the surgical management of ovarian cancer, few may feel comfortable performing such extensive and radical upper abdominal procedures. Third, despite our attempt to achieve cytoreduction to NGR in all patients, 4/11 patients had residual disease (three with \(<1.0\) cm, and one with \(>1.0\) cm). Although the resection of CPLNs certainly contributed to achieving optimal cytoreduction to \(\leq1.0\) cm in these three patients, an alternative approach would be to perform this procedure last after ensuring NGR in the remainder of the abdomen. Considering the impact of tumor biology and initial disease burden on PFS/OS, it may be prudent to ensure ability to achieve NGR prior to performing this specific procedure. Lastly, all patients had surgery performed at a major university-based hospital with physicians and staff that were highly experienced in managing potentially serious post-operative complications. Smaller hospitals with less experienced consulting physicians and ancillary staff may be reluctant to perform such aggressive surgical procedures in fear of potentially catastrophic events.

In conclusion, our small case series demonstrates the feasibility and short-term morbidities associated with transdiaphragmatic CPLN resection and describes an additional procedure used to achieve cytoreduction to NGR in patients with advanced gynecologic malignancies.

**Conflict of interest statement**

None of the authors have any potential conflicts of interest to declare.

**References**

Aletti, G.D., Dowdy, S.C., Gostout, B.S., et al., 2006. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 (1), 77–85.

Aletti, G.D., Long, H.J., Podratz, K.C., Cliby, W.A., 2007. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol. Oncol. 104 (1), 212–216.

American Cancer Society, Inc. Cancer Facts & Figures 2015. Available at: www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (Accessed on: May 25, 2015).

Bashir, S., Gerardi, M.A., Giuntoli 2nd, R.L., Montes, T.P., Bristow, R.E., 2010. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol. Oncol. 119 (2), 235–258.
Benedetti Panici, P., Di Donato, V., Fischetti, M., et al., 2015. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol. Oncol. 137 (3), 406–411.

Chi, D.S., Zivanovic, O., Levinson, K.L., et al., 2010. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol. Oncol. 119 (1), 38–42.

Cliby, W., Dowdy, S., Feitoza, S.S., Gostout, B.S., Podratz, K.C., 2004. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol. Oncol. 94 (3), 655–660.

Eisenhauer, E.L., Abu-Rustum, N.R., Sonoda, Y., et al., 2006. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol. Oncol. 103 (3), 1083–1090.

Eisenkop, S.M., Spirtos, N.M., 2001. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol. Oncol. 82 (3), 489–497.

LaFargue, C.J., Bristow, R.E., 2015. Transdiaphragmatic cardiophrenic lymph node resection for stage IV ovarian cancer. Gynecol. Oncol. 138 (3), 762–763.

Lim, M.C., Lee, H.S., Jung, D.C., Choi, J.Y., Seo, S.S., Park, S.Y., 2009. Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann. Surg. Oncol. 16 (7), 1990–1996.

Pecorelli, S., Creasman, W., Petterson, F., Benedict, J., Shepard, J., 1998. FIGO annual report on the results of treatment in gynaecological cancer. J. Epidemiol. Biostat. 3, 75–102.

Sandadi, S., Long, K., Andikyan, V., et al., 2014. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecol. Oncol. 132 (2), 299–302.

Tsolakidis, D., Amant, F., Van Gorp, T., Leunen, K., Neven, P., Vergote, I., 2010. Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB–IV epithelial ovarian cancer. Gynecol. Oncol. 116 (3), 489–496.

Winter 3rd, W.E., Maxwell, G.L., Tian, C., et al., 2008. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 26 (1), 83–89.